Adapsyn Bioscience is a chemical bioinformatics company that specializes in discovering and developing novel small molecule therapeutics derived from microbial sources. Utilizing advanced genomics and metabolomics platforms, the company identifies and characterizes drug-like compounds for applications in drug discovery, agriculture, and food and nutrition. Their unique approach allows for the rapid screening of thousands of compounds, leading to the identification of promising candidates for various therapeutic indications. Founded in 2016 and backed by notable investors, Adapsyn is positioned to make significant contributions to the biotechnology and pharmaceutical sectors, particularly in addressing urgent health challenges such as tuberculosis.
Something looks off?